Sayantan Bose

Sayantan Bose

Auto-generated profile, based on publicly available information

Sayantan Bose

Division of Molecular Medicine, Bose Institute, Calcutta Improvement Trust Scheme VII M, Kolkata, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
SPSubhadip Pati
Subhadip Pati
SMSumon Mukherjee
Sumon Mukherjee
SDSaikat Dutta
Saikat Dutta
AGAharna Guin
Aharna Guin
DRDia Roy
Dia Roy
GSGaurisankar Sa
Gaurisankar Sa
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.

22 October 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TATimna Agur
Timna Agur
JWJohannes Wedel
Johannes Wedel
SBSayantan Bose
Sayantan Bose
ASA. G. Pramoda Sahankumari
A. G. Pramoda Sahankumari
DGDaniel Goodman
Daniel Goodman
DBDavid M. Briscoe
David M. Briscoe
The statin family of therapeutics is widely used clinically as cholesterol lowering agents, and their effects to target intracellular mevalonate production is a key mechanism of action. In this study, we performed full transcriptomic RNA sequencing and qPCR to evaluate the effects of mevalonate on the immunoregulatory phenotype of endothelial cells (EC). We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9). In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+CD4+ T cell proliferation as well as IL-2, IFNγ and IL-6 production versus vehicle-treated EC. In contrast, pre-treatment of EC with L-mevalonate in combination with simvastatin reversed phenotypic and functional responses. Collectively, these results indicate that relative mevalonate metabolism by EC is critical to sustain EC-dependent mechanisms of immunity. Our findings have broad relevance for the repurposing of statins as therapeutics to augment immunoregulation and/or to inhibit local tissue pro-inflammatory cytokine production following transplantation.


18 May 2019 in The Nucleus
Verified
Journal Article
Open access
PDF file
DCDwaipayan Chakraborty
Dwaipayan Chakraborty
SPSubhadip Pati
Subhadip Pati
SBSayantan Bose
Sayantan Bose
SDSubhanki Dhar
Subhanki Dhar
SDSaikat Dutta
Saikat Dutta
GSGaurisankar Sa
Gaurisankar Sa
One of the major emerging modes of treatment for cancer patients in the current healthcare systems has been immunotherapy. Various approaches of immunotherapy have been proved to be useful against tumor progression in laboratory settings. Few have also been showing promising results in clinical trials. However, many clinical trials have also pointed out the adverse side effects of immunotherapy on tumor patients. In this context, we discuss about the success and failures of the present modes of immunotherapy available to patients and also about the emerging target points that are coming up and may be crucial in the success of future immunotherapy. The upcoming researches involving new players in the immunotherapy arena like Breg and Treg and how combinatorial therapies will be needed to counter the side effects that are exhibited by the present techniques of immunotherapy have been discussed in the review. This review will provide a broad picture of the current scenario of cutting edge immunotherapy and the newer methods that can be utilized to prevent the failures and ensure success in future clinical trials involving immunotherapy.

4 April 2023
Verified
Other
Open access
SPSubhadip Pati
Subhadip Pati
SMSumon Mukherjee
Sumon Mukherjee
SDSaikat Dutta
Saikat Dutta
AGAharna Guin
Aharna Guin
DRDia Roy
Dia Roy
GSGaurisankar Sa
Gaurisankar Sa
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.

26 November 2025
Verified
Other
Open access
SPSubhadip Pati
Subhadip Pati
SMSumon Mukherjee
Sumon Mukherjee
SDSaikat Dutta
Saikat Dutta
AGAharna Guin
Aharna Guin
DRDia Roy
Dia Roy
GSGaurisankar Sa
Gaurisankar Sa
B cells are an essential component of humoral immunity. Their primary function is to mount antigen-specific antibody responses to eliminate pathogens. Despite an increase in B-cell number, we found that serum-IgG levels were low in patients with breast cancer. To solve this conundrum, we used high-dimensional flow cytometry to analyze the heterogeneity of B-cell populations and identified a tumor-specific CD19+CD24hiCD38hi IL10-producing B regulatory (Breg)–cell subset. Although IL10 is a Breg-cell marker, being an intracellular protein, it is of limited value for Breg-cell isolation. Highly expressed Breg-cell surface proteins CD24 and CD38 also impede the isolation of viable Breg cells. These are hurdles that limit understanding of Breg-cell functions. Our transcriptomic analysis identified, CD39-negativity as an exclusive, sorting-friendly surface marker for tumor-associated Breg cells. We found that the identified CD19+CD39‒IL10+ B-cell population was suppressive in nature as it limited T helper–cell proliferation, type-1 cytokine production, and T effector–cell survival, and augmented CD4+FOXP3+ regulatory T–cell generation. These tumor-associated Breg cells were also found to restrict autologous T follicular helper–cell expansion and IL21 secretion, thereby inhibiting germinal transcript formation and activation-induced cytidine deaminase expression involved in H-chain class-switch recombination (CSR). This isotype-switching abnormality was shown to hinder B-cell differentiation into class-switched memory B cells and subsequent high-affinity antibody-producing plasma B cells, which collectively led to the dampening of IgG-mediated antibody responses in patients with cancer. As low IgG is associated with poor prognosis in patients with cancer, Breg-cell depletion could be a promising future therapy for boosting plasma B cell–mediated antibody responses.